Literature DB >> 8148809

Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism.

N Okabe1, N Hashizume.   

Abstract

Binding properties of Sudlow's site-specific drugs to glycosylated human serum albumin (G-HSA) were investigated using fluorescence and circular dichroism (CD). Dansylamide, phenylbutazone and warfarin were used as site I-specific drugs, and dansylproline, ibuprofen and flufenamic acid were used as site II-specific ones. Similar changes in the fluorescence intensity of dansylamide occurred in the presence of both G-HSA and intact human serum albumin (HSA), while the fluorescence enhancement of dansylproline caused by G-HSA was extremely weakened in comparison with that by HSA. These results suggest that the glycosylation of HSA inhibits the binding of the site II-specific drug, dansylproline, to HSA, while it does not influence the binding of the site I specific drug, dansylamide. The induced ellipticities of the complexes of ibuprofen, flufenamic acid and phenyl butazone with G-HSA were diminished in comparison with those with HSA. With the complexes of warfarin, the induced ellipticity was enhanced. These CD results suggest that the glycosylation of HSA induces microenvironmental changes in the binding sites for the above site-specific drugs which influence the drug binding ability of HSA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148809     DOI: 10.1248/bpb.17.16

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  12 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 3.  An overview of in vitro and in vivo glycation of albumin: a potential disease marker in diabetes mellitus.

Authors:  Km Neelofar; Jamal Ahmad
Journal:  Glycoconj J       Date:  2017-08-15       Impact factor: 2.916

4.  Does glimepiride alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy animals: investigating mechanism of interaction by molecular modeling studies.

Authors:  Alok Shiomurti Tripathi; Ajay Kumar Timiri; Papiya Mitra Mazumder; Anil Chandewar
Journal:  J Mol Model       Date:  2015-10-01       Impact factor: 1.810

Review 5.  Review: modifications of human serum albumin and their binding effect.

Authors:  Philbert Lee; Xiaoyang Wu
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  An evaluation of a fluorometric method for determining binding parameters of drug-carrier complexes using mathematical models based on total drug concentration.

Authors:  Boontarika Chanvorachote; Ubonthip Nimmannit; Walaisiri Muangsiri; Lee Kirsch
Journal:  J Fluoresc       Date:  2009-04-08       Impact factor: 2.217

7.  Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients.

Authors:  Anisha E Mendonza; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 8.  Review: Glycation of human serum albumin.

Authors:  Jeanethe Anguizola; Ryan Matsuda; Omar S Barnaby; K S Hoy; Chunling Wa; Erin DeBolt; Michelle Koke; David S Hage
Journal:  Clin Chim Acta       Date:  2013-07-24       Impact factor: 3.786

9.  Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy.

Authors:  Alok S Tripathi; Papiya M Mazumder; Anil V Chandewar
Journal:  J Diabetes Metab Disord       Date:  2014-01-07

10.  Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.

Authors:  Khalid M Alkharfy
Journal:  Exp Diabetes Res       Date:  2009-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.